Company Overview and News
2018-10-09 seekingalpha - 1
WallStars are distinguished by positive broker target price upsides. Industrial Metals, Chemicals, Coal, Steel, Lumber & Wood, and Paper topped October's Basic Materials WallStars for net gains calculated 10/5/18.
ARLP CCR TGLS GFI.WI SXCP DRD MLDUR FELP ANDA NBRXF DRDGF HCLP TGLSW GGB GSM BAK SWM EVA GFIOF SQM SID WPM OLN VHI CINR WLKP OSB KRO TX GFI ANDAW HPCO
Top 10 10%+ "Safer" Dividend WallStar annual yields ranged from 11.65% to 24.87%. Their free cash flow yields ranged from 13.01% to 77.86%.
CPLP SXCP ANH ORC EARN WMC SNMP TCRX DX NLY TCRD TCRZ TSLF GMLP GPP
From 8/15/18-9/17/18, Fredrik Arnold dividend "followers" commented on 40 equities and funds. Some comments were bad news, so some rogues mixed in to create a FollowerFavorite/Rogue (FoFa/Ro) list.
KWH.UN VOD VOD SXCP CRIUF ORC DVDDF CHMI CZZ CJREF CIM GMLP VODPF CJR.B CVX AVGO BRCM INTC SNMP
WallStars show positive broker target-price-upsides. 15 of 80 were tagged as "safer" for dividends because they showed positive one-year returns and free-cash-flow-yields greater than their dividend-yields 9/14/18.
CPLP SXCP ANH ORC SUN TWO SNMP TCRX DX NLY SFL TCRD TCRZ TSLF GMLP SIR GPP
2018-09-08 seekingalpha - 1
WallStars show positive broker target price upsides. 39 of 68 WallStar stocks were tagged "safer" for dividends by showing positive annual returns, and free cash flow yields beyond their dividend yields 8/31/18.
RIO RIO BLT SXCP VALE3 NBRXF RRS PKX RTPPF HUN MERC RTNTF SWM CC OLN WLK BHPBF RGORF GOLD OSB GOLD MRI.U KRO BHP RIO BBL BHP BHPLF
2018-09-06 seekingalpha - 3
WallStars are distinguished by positive broker target price upsides. Industrial Metals, Coal, Steel, and Gold, topped August-September's Basic Materials WallStars for net gains calculated 8/31/18.
CCR TGLS CINR SXCP WLK RGORF FELP GOLD WLKP RRS GOLD HCLP GSM KRO SWM EVA IPHS
WallStars show positive broker target price upsides. 14 of 78 10%+ Yield WallStars were "safer" for dividends showing positive one-year returns and free cash flow yields greater than dividend yields 8/31/18.
CPLP SXCP ANH NBRXF ORC CIM SUN SNMP TCRX KDP DX TCRD TCRZ OSB VEDL TSLF GMLP GPP VEDL
Good morning. My name is Wendy, and I will be a conference operator today. At this time, I would like to welcome everyone to SunCoke Energy Partners Second Quarter 2018 Earnings Conference Call. All lines have been placed on mute to prevent any background noise. After the speakers’ remarks there will be a question-and-answer session. [Operator Instructions] Thank you.
The following slide deck was published by SunCoke Energy Partners in conjunction with their 2018 Q2 earnings call.
Document Table of Contents
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
WallStars show positive broker target price upsides. 32 of 54 WallStar stocks were tagged "safer" for dividends by showing positive annual-returns, and free cash-flow yields beyond their dividend yields 7/20/18.
RIO RIO BLT SXCP RRS PKX RTPPF HUN MERC RTNTF SWM OLN BHPBF WLK LYB RGORF GOLD DWDP OSB GOLD MRI.U BHP RIO LALWF BBL BHP BHPLF
2018-07-24 seekingalpha - 2
WallStars are distinguished by positive broker target price upsides. Industrial Metals, Gold, Specialty Chemicals, Steel, & Coal topped July's Basic Materials WallStars for net gains calculated 7/20/18.
ARLP CCR GSM TGLS DRD SXCP CINR WLK GPRE EVA PKX
26 of 82 stocks sporting 10%+ yields were tagged as "safer" for dividends because they showed positive 1-year returns and free cash flow yields greater than their dividend yields on 7/3/18.
AIY TCRX AINV SXCP CRIUF AIB ORC TCRD TCRZ TEO VEDL TSLF KIROY KUMBF GMLP CAPL EARN SUN VEDL SNMP
16 of 75 Wall St. favorites sporting 9%+ yields were tagged as "safer" for dividends because they showed positive one-year returns and free cash flow yields greater than their dividend yields 6/20/18.
AIY TCRX AINV HMLP SXCP DX AIB ORC TCRD TCRZ TSLF GMLP CAPL SUN SNMP
2018-10-01 - Asif
Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...
2018-09-25 - Asif
Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...
as of ET